An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Actimed, a biotech company, says it has finished signing up patients for a clinical study that combines two drugs: S‑pindolol and semaglutide. The trial is called PROACT and is testing whether adding S‑pindolol to semaglutide helps people lose more weight or keep more muscle than semaglutide alone. Completion of enrollment just means they have the number of participants they planned to include and can move on to running the study and collecting results. Semaglutide is the familiar active ingredient in medicines like Ozempic and Wegovy. It acts like a natural gut hormone that tells your brain you’re full and slows how fast your stomach empties, so people tend to eat less and lose weight. S‑pindolol is less well known; it’s a variant of the beta‑blocker pindolol but is being investigated for effects on appetite, metabolism, and especially preserving muscle mass during weight loss. In plain terms, the idea is semaglutide helps people lose weight, and S‑pindolol might help protect against losing muscle while that happens. What the trial is actually doing is testing that combination in a controlled way. “Completed enrollment” only tells us they’ve signed up enough people; it doesn’t say anything about results yet. We don’t know whether the trial is in healthy volunteers or people with obesity, how long it will run, or exactly how many participants were enrolled from the short headline alone. Until the company publishes data — usually after the trial ends and results are analyzed — we won’t know whether the combination produces a meaningful benefit or by how much. Why this could matter: many people who lose weight with potent drugs also lose some muscle, which can affect strength, metabolism, and how the body responds to future dieting. If adding a drug like S‑pindolol preserves muscle without reducing the weight‑loss benefit, that would be useful for people using semaglutide for obesity or related conditions. Clinicians, people taking semaglutide, and companies in the obesity treatment space would pay attention because it could change how combination therapies are prescribed or developed. There are important caveats. Enrollment completion is an early administrative milestone, not proof of effectiveness or safety. S‑pindolol is investigational in this context, and combining drugs can bring unexpected side effects or interactions. We don’t know regulatory status from this notice — whether authorities have approved the combination or whether it’s experimental only inside the trial. People should not try to combine these drugs outside a doctor’s guidance or a clinical study. The final verdict depends on the trial’s carefully measured results and subsequent review by independent experts and regulators. Bottom line: Actimed has finished signing up people for a trial testing whether adding S‑pindolol to semaglutide can protect muscle during weight loss — it’s a promising idea, but we need the trial results before we know if it actually works or is safe.
Source: The Clinical Trial Vanguard